Vergleich

MOUSE ANTI HUMAN CD154 (SOLUBLE)

ArtNr 20-783-314437
Hersteller GENWAY
Menge 0.2 mg
Kategorie
Typ Antibody
Applikationen WB
Specific against Human (Homo sapiens)
Host Mouse
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias GWB-3E40C0
Similar products 20-783-314437
Lieferbar
Genway ID:
GWB-3E40C0
Specificity:
CD154 (SOLUBLE)
Isotype:
IgG1
Preparation:
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution:
Phosphate buffered saline pH7. 4
Preservative Stabilisers:
0. 09% Sodium Azide (NaN3)Approx. Protein Concentrations: IgG concentration 1. 0mg/ml
Immunogen:
Recombinant human soluble CD154 conjugated to BSA.
Specificity:
Recognises human CD154 a 32kD glycoprotein also known as CD40 ligand. It is a member of the TNF family of molecules. It binds to CD40 and acts as a co-stimulatory molecule by activating antigen presenting cells such as B cells. While CD154 is mostly found expressed on activated T cells
Specificity:
Recognises the soluble form of the protein. Recommended Secondary Antibodies: Rabbit Anti Mouse IgGGoat Anti Mouse IgGGoat Anti Mouse IgG (H/L)Goat Anti Mouse IgG IgA IgMHuCAL Anti Mouse IgG1Goat Anti Mouse IgG (Fc)Sheep Anti Mouse IgG (H/L)
Function:
Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching. Ref. 10Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa actin polymerization and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway. Ref. 10Subunit structureHomotrimer. Subcellular locationCell membrane; Single-pass type II membrane protein. CD40 ligand soluble form: Secreted. Tissue specificitySpecifically expressed on activated CD4+ T-lymphocytes. Post-translational modificationThe soluble form derives from the membrane form by proteolytic processing. N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40. Not O-glycosylated. Ref. 9Involvement in diseaseDefects in CD40LG are the cause of X-linked immunodeficiency with hyper-IgM type 1 (HIGM1) [MIM:308230]; also known as X-linked hyper IgM syndrome (XHIM). HIGM1 is an immunoglobulin isotype switch defect characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. Affected males present at an early age (usually within the first year of life) recurrent bacterial and opportunistic infections including Pneumocystis carinii pneumonia and intractable diarrhea due to cryptosporidium infection. Despite substitution treatment with intravenous immunoglobulin the overall prognosis is rather poor with a death rate of about 10% before adolescence. Ref. 3Ref. 13Ref. 14Ref. 15Ref. 16Ref. 17Ref. 18Ref. 19Ref. 20Ref. 21Sequence similaritiesBelongs to the tumor necrosis factor family. [1] \" Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. \" Tashiro K. Tada H. Heilker R. Shirozu M. Nakano T. Honjo T. Science 261:600-603(1993) [PubMed: 8342023] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA). [2] \" Molecular cloning of TPAR1 a gene whose expression is repressed by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA). \" Jiang W. Zhou P. Kahn S. M. Tomita N. Johnson M. D. Weinstein I. B. Exp. Cell Res. 215:284-293(1994) [PubMed: 7982471] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA). [3] \" Molecular cloning and structure of a pre-B-cell growth-stimulating factor. \" Nagasawa T. Kikutani H. Kishimoto T. Proc. Natl. Acad. Sci. U. S. A. 91:2305-2309(1994) [PubMed: 8134392] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA). [4] Nomura M. Nakata Y. Uzawa A. Nose M. Akashi M. Suzuki G. Submitted (DEC-1994) to the EMBL/GenBank/DDBJ databasesCited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA). Strain: AKR/J. [5] \" The transcriptional landscape of the mammalian genome. \" Carninci P. Kasukawa T. Katayama S. Gough J. Frith M. C. Maeda N. Oyama R. Ravasi T. Lenhard B. Wells C. Kodzius R. Shimokawa K. Bajic V. B. Brenner S. E. Batalov S. Forrest A. R. Zavolan M. Davis M. J. Wilming L. G. Aidinis V. Allen J. E. Ambesi-Impiombato A. Apweiler R. Aturaliya R. N. Bailey T. L. Bansal M. Baxter L. Beisel K. W. Bersano T. Bono H. Chalk A. M. Chiu K. P. Choudhary V. Christoffels A. Clutterbuck D. R. Crowe M. L. Dalla E. Dalrymple B. P. de Bono B. Della Gatta G. di Bernardo D. Down T. Engstrom P. Fagiolini M. Faulkner G. Fletcher C. F. Fukushima T. Furuno M. Futaki S. Gariboldi M. Georgii-Hemming P. Gingeras T. R. Gojobori T. Green R. E. Gustincich S. Harbers M. Hayashi Y. Hensch T. K. Hirokawa N. Hill D. Huminiecki L. Iacono M. Ikeo K. Iwama A. Ishikawa T. Jakt M. Kanapin A. Katoh M. Kawasawa Y. Kelso J. Kitamura H. Kitano H. Kollias G. Krishnan S. P. Kruger A. Kummerfeld S. K. Kurochkin I. V. Lareau L. F. Lazarevic D. Lipovich L. Liu J. Liuni S. McWilliam S. Madan Babu M. Madera M. Marchionni L. Matsuda H. Matsuzawa S. Miki H. Mignone F. Miyake S. Morris K. Mottagui-Tabar S. Mulder N. Nakano N. Nakauchi H. Ng P. Nilsson R. Nishiguchi S. Nishikawa S. Nori F. Ohara O. Okazaki Y. Orlando V. Pang K. C. Pavan W. J. Pavesi G. Pesole G. Petrovsky N. Piazza S. Reed J. Reid J. F. Ring B. Z. Ringwald M. Rost B. Ruan Y. Salzberg S. L. Sandelin A. Schneider C. Schoenbach C. Sekiguchi K. Semple C. A. Seno S. Sessa L. Sheng Y. Shibata Y. Shimada H. Shimada K. Silva D. Sinclair B. Sperling S. Stupka E. Sugiura K. Sultana R. Takenaka Y. Taki K. Tammoja K. Tan S. L. Tang S. Taylor M. S. Tegner J. Teichmann S. A. Ueda H. R. van Nimwegen E. Verardo R. Wei C. L. Yagi K. Yamanishi H. Zabarovsky E. Zhu S. Zimmer A. Hide W. Bult C. Grimmond S. M. Teasdale R. D. Liu E. T. Brusic V. Quackenbush J. Wahlestedt C. Mattick J. S. Hume D. A. Kai C. Sasaki D. Tomaru Y. Fukuda S. Kanamori-Katayama M. Suzuki M. Aoki J. Arakawa T. Iida J. Imamura K. Itoh M. Kato T. Kawaji H. Kawagashira N. Kawashima T. Kojima M. Kondo S. Konno H. Nakano K. Ninomiya N. Nishio T. Okada M. Plessy C. Shibata K. Shiraki T. Suzuki S. Tagami M. Waki K. Watahiki A. Okamura-Oho Y. Suzuki H. Kawai J. Hayashizaki Y. Science 309:1559-1563(2005) [PubMed: 16141072] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). Strain: C57BL/6J. Tissue: Embryo and Kidney. [6] \" The status quality and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). \" The MGC Project TeamGenome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). Strain: C57BL/6J. Tissue: Mammary gland.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 0.2 mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen